Hereditary Angioedema Therapeutics Market (2026 to 2035)

Hereditary Angioedema Therapeutics Market Summary:

The global Hereditary Angioedema (HAE) therapeutics market size was valued at approximately USD 3,165 Million in 2025 and is projected to reach USD 7,205 Million by 2035, expanding at a CAGR of 8.56% from 2026 to 2035. Market growth is driven by increasing approvals of novel therapies such as oral kallikrein inhibitors, RNA-targeted treatments and monoclonal antibodies, rising awareness of this rare genetic disorder, expanding access to molecular diagnostics for C1-INH deficiency, and growing adoption of long-term prophylaxis strategies in both developed and emerging economies.

Hereditary Angioedema Therapeutics Market Revenue Forecast, 2022–2035 (US$ Million)

Years	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035
Revenue (USD Mn)	2,520	2,715	2,930	3,165	3,435	3,725	4,040	4,385	4,760	5,170	5,615	6,100	6,630	7,205

Key Market Takeaways & Insights

• The United States Hereditary Angioedema Therapeutics market held the largest share of 49.0% of the global market in 2025.
• The Hereditary Angioedema Therapeutics industry in Asia Pacific is expected to grow 11.60% significantly over the forecast period.
• By drug class, the C1-esterase inhibitors (C1-INH) segment held the largest market share of 48.60% in 2025.
• By treatment type, the prophylaxis segment held the largest market share of 67.80% in 2025.
• By route of administration, the subcutaneous administration segment held the largest market share of 46.50% in 2025.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Hereditary Angioedema Therapeutics Market Size: USD 3,165 Million
• 2032 Hereditary Angioedema Therapeutics Market Size: USD 7,205 Million
• CAGR (2026-2035): 8.56%

Hereditary Angioedema Therapeutics Market Regional Forecast Analysis, 2026–2035 (US$ Million)

Region	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035
North America	1,298	1,385	1,480	1,576	1,660	1,818	1,951	2,096	2,248	2,414	2,594	2,791	3,003	3,228
Europe	794	837	920	988	1,047	1,155	1,248	1,350	1,462	1,582	1,713	1,848	2,002	2,162
Asia Pacific	257	279	322	367	404	466	525	592	672	755	854	956	1,071	1,210
Latin America	106	114	126	142	155	175	194	215	232	257	286	308	340	389
Middle East & Africa	65	72	82	92	101	112	122	131	139	161	168	177	193	216

Disease Epidemiology Analysis:

• Rising Burden of Hereditary Angioedema Globally
• Growing Incidence of C1-INH Deficiency
• Increasing Genetic Disorder Awareness
• Need for Early Disease Detection & Diagnosis

Treatment Landscape Overview

• HAE is a Rare Genetic Disorder Requiring Specialized Therapeutics
• Acute Attack Management (On-demand Treatment)
• Long-term Prophylaxis Management
• Emerging Gene Therapy & RNA-targeted Approaches

Hereditary Angioedema Therapeutics Market Outlook Analysis Conservative, Likely, Optimistic, (US$ Million), 2025–2035

	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035
Conservative	3,165	3,360	3,575	3,800	4,040	4,300	4,580	4,880	5,200	5,545	5,915
Likely	3,165	3,435	3,725	4,040	4,385	4,760	5,170	5,615	6,100	6,630	7,205
Optimistic	3,165	3,540	3,955	4,420	4,940	5,520	6,170	6,895	7,705	8,610	9,620

Market Dynamics:

Market Drivers:

Rising Global Burden of Hereditary Angioedema and Rare Genetic Disorders

Hereditary angioedema (HAE) is a rare but potentially life-threatening autosomal dominant genetic disorder caused by deficiency or dysfunction of the C1 esterase inhibitor (C1-INH) protein. HAE affects an estimated 1 in 50,000 individuals globally, with a pooled global prevalence of 1.22 cases per 100,000 people based on a systematic review and meta-analysis of 24 studies published between 2000 and 2024, including 11,245 HAE cases. The disease is characterized by recurrent, unpredictable attacks of severe swelling affecting the abdomen, extremities, face, and airways. Without effective therapeutic intervention, laryngeal edema carries a mortality risk of 20–25%. In the United States alone, HAE episodes result in an estimated 15,000 to 30,000 annual emergency department admissions. This growing recognition of the disease burden, combined with improved diagnostic capabilities and rising healthcare awareness, is significantly driving demand for HAE therapeutics globally.

Expanding Pipeline of Novel HAE Therapeutics and Recent FDA/EMA Approvals

The HAE therapeutics landscape has witnessed an unprecedented wave of regulatory approvals in 2024–2025. The U.S. Food and Drug Administration (FDA) approved EKTERLY (siderostat) in July 2025, the first and only oral plasma kallikrein inhibitor for on-demand treatment of acute HAE attacks in patients aged 12 years and older, offering a major shift from injection-based options. In August 2025, the FDA approved DAWNZERA (dominators), the first RNA-targeted medicine for HAE prophylaxis. Additionally, ANDEMBRY (garadacimab-gxii), the first once-monthly subcutaneous Factor XIIa inhibitor for HAE prophylaxis, was approved by the FDA in June 2025. The European Commission granted marketing authorization to EKTERLY in September 2025 (with Germany launch in Q4 2025) and to DAWNZERA in January 2026. These landmark approvals are substantially expanding the addressable patient population and driving market revenue.

Market Restraint:

High Cost of HAE Therapeutics and Reimbursement Challenges

HAE therapeutics are among the most expensive rare disease treatments globally. Biologic agents such as lanadelumab (Takhzyro) and plasma-derived C1-INH concentrates require chronic administration and involve very high costs per patient. Many healthcare systems, particularly in low- and middle-income countries (LMICs), struggle to provide adequate reimbursement coverage for these expensive orphan-designated medicines. In high-income countries, complex insurance pre-authorization processes, payer restrictions, and budget impact concerns further delay patient access. The high therapy costs create significant economic barriers, particularly for healthcare systems in Latin America, Asia Pacific, the Middle East, and Africa, where HAE is often underdiagnosed and undertreated. These financial barriers restrict market penetration despite a growing unmet need for advanced HAE therapies.

Underdiagnosis and Significant Diagnostic Delays

Despite advancements in diagnostic methods, hereditary angioedema remains significantly underdiagnosed globally, particularly in Asia Pacific, Latin America, the Middle East, and Africa. Many patients experience diagnostic delays of several years to over a decade before receiving an accurate HAE diagnosis, exposing them to high risks of fatal laryngeal attacks and unnecessary procedures. A 2024 survey of US physicians indicated that fewer than 38% of patients received an accurate HAE diagnosis within 1–3 years of symptom onset. In the Asia Pacific region, the overall minimal prevalence has been estimated at 0.02 per 100,000, far below expected rates, reflecting significant under-detection due to limited C1-INH testing availability, lack of regional guidelines, and low physician awareness. Until diagnostic gaps are addressed, the full addressable patient population cannot be reached, limiting the market's growth potential.

Market Opportunities:

Transition to Oral and Self-Administered Therapies Expanding Patient Access

The approval and commercial launch of sebetralstat (EKTERLY), the first oral on-demand treatment for HAE attacks, represents a transformational opportunity in the HAE therapeutics market. Oral therapies eliminate the need for intravenous or subcutaneous injections, simplifying treatment especially during sudden attacks. Data from the KONFIDENT Phase 3 trial showed median symptom relief within 1.61 hours with oral sebetralstat 300 mg versus 6.72 hours with placebo. Furthermore, once-daily oral berotralstat (ORLADEYO, BioCryst) has already achieved USD 437 million in 2024 sales, with 70% of U.S. HAE patients now choosing oral prophylaxis. This shift toward patient-friendly oral formulations and the convenience of subcutaneous autoinjectors for RNA-targeted agents such as dominators (every 4–8 weeks) is expected to meaningfully expand the treatable patient pool globally, boosting market revenue significantly through 2035.

Hereditary Angioedema Therapeutics Market Share Analysis by Segments, 2025 (%)

By Segments	2025
Drug Class	C1-Esterase Inhibitors (C1-INH) 48.6%
Treatment Type	Prophylaxis Treatment 67.8%
Route of Administration	Subcutaneous 46.5%
End User	Hospitals & Specialty Clinics 47.2%

Hereditary Angioedema Therapeutics Market Segmentations Analysis:

By Drug Class: C1-Esterase Inhibitors (C1-INH), Kallikrein Inhibitors, Bradykinin B2 Receptor Antagonists, RNA-targeted Agents/Antisense Oligonucleotides, Gene Therapy Candidates, Others

C1-Esterase Inhibitors (C1-INH) – Dominating Segment

Held the largest market share due to the wide clinical use of plasma-derived and recombinant C1-INH concentrates such as Berinert, Haegarda, Cinryze, and Recontest for both acute attack treatment and long-term prophylaxis. Strong real-world evidence, broad regulatory approval, and established supply chains support their dominant position.

By Treatment Type: Prophylaxis Treatment, On-demand (Acute Attack) Treatment

Prophylaxis Treatment – Dominating Segment

Accounted for the largest market share due to strong patient preference for attack prevention, growing adoption of long-term prophylactic agents (lanadelumab, berotralstat, C1-INH), and increasing clinical guideline recommendations for prophylaxis in patients with frequent or severe attacks.

By Route of Administration: Subcutaneous, Intravenous, Oral

Subcutaneous Administration – Dominating Segment

Dominated the market due to the widespread use of subcutaneous formulations of lanadelumab, C1-INH concentrate (Haegarda), and newly approved donidalorsen, as well as patient preference for self-administration at home versus intravenous infusions.

By End Use: Hospitals & Specialty Clinics, Specialty Pharmacies, Home Care Settings, Academic & Research Institutes, Contract Research Organizations (CROs).

Hospitals & Specialty Clinics – Dominating Segment

Held the largest market share due to high patient volumes managed by allergy/immunology specialists, established infusion facilities for IV C1-INH products, and growing number of Angioedema Centers of Reference and Excellence (ACAREs).

Market Regional Insights:

Hereditary Angioedema Therapeutics Market Regional Analysis and Forecast, 2022–2025–2032

By Geography	2022	2025	2032
North America	51.50%	49.80%	44.80%
US	91.50%	91.00%	89.50%
Canada	8.50%	9.00%	10.50%
Europe	31.50%	31.20%	30.00%
Germany	22.00%	22.20%	22.50%
UK	16.00%	16.20%	16.50%
France	13.00%	13.10%	13.30%
Italy	10.50%	10.30%	9.80%
Spain	8.50%	8.70%	9.20%
Switzerland	6.50%	6.70%	7.20%
Netherlands	6.00%	6.20%	6.60%
Rest of Europe	17.50%	16.60%	14.90%
Asia Pacific	10.20%	11.60%	16.80%
China	31.00%	32.00%	34.50%
India	8.50%	10.00%	13.50%
Japan	28.50%	27.00%	22.50%
South Korea	8.00%	8.40%	9.50%
Australia	10.00%	9.60%	8.50%
Singapore	2.80%	2.70%	2.50%
Thailand	2.80%	3.10%	4.20%
Malaysia	2.30%	2.50%	3.10%
Indonesia	3.10%	3.40%	4.40%
Rest of Asia Pacific	3.00%	1.30%	1.30%
Middle East & Africa	2.60%	2.90%	3.00%
Saudi Arabia	19.00%	20.00%	23.00%
United Arab Emirates	12.00%	13.00%	16.00%
South Africa	35.00%	33.00%	28.00%
Israel	17.00%	17.50%	18.50%
Egypt	6.00%	6.50%	8.00%
Rest of MEA	11.00%	10.00%	6.50%
Latin America	4.20%	4.50%	5.40%
Brazil	45.00%	44.00%	42.00%
Mexico	22.00%	23.00%	25.00%
Argentina	10.50%	10.20%	9.50%
Chile	5.50%	5.80%	6.50%
Colombia	8.00%	8.20%	9.00%
Peru	3.50%	3.70%	4.10%
Rest of LA	5.50%	5.10%	3.90%

North America Hereditary Angioedema Therapeutics Market Analysis:

North America Hereditary Angioedema Therapeutics market held the largest share of the global market in 2025. The regional market is primarily driven by the strong presence of leading biopharmaceutical companies specializing in rare diseases, high healthcare expenditure, well-established orphan drug development frameworks, and rapid adoption of novel HAE treatments including oral kallikrein inhibitors and RNA-targeted therapies.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 North America Hereditary Angioedema Therapeutics Market Size: USD 1,576 Million

• 2035 North America Hereditary Angioedema Therapeutics Market Size: USD 3,228 Million

• North America Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 8.56%

Drivers

• Strong presence of leading rare disease biopharmaceutical companies

• High healthcare expenditure and advanced insurance coverage

• Rapid adoption of new oral and RNA-targeted HAE therapies

• Growing prevalence of diagnosed HAE with improved awareness

Restraints

• High cost of HAE biologics and specialty therapies

• Stringent FDA regulatory requirements for rare disease approval

• Reimbursement challenges for newly approved novel agents

• Shortage of specialist allergy/immunology physicians

Opportunities

• Expansion of oral and self-administered HAE therapies

• Gene therapy and RNA-targeted pipeline development

United States Hereditary Angioedema Therapeutics Market Analysis:

The U.S. accounted for the dominant share within North America and represented approximately 91.00% of the global Hereditary Angioedema Therapeutics market in 2025. The U.S. HAE therapeutics market was supported by strong biopharmaceutical innovation, extensive R&D investments, and large-scale specialty pharmacy distribution.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 United States Hereditary Angioedema Therapeutics Market Size: USD 1,434 Million

• 2035 Untitled States Hereditary Angioedema Therapeutics Market Size: USD 2,889 Million

• United States Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 8.40%

Drivers

• Large-scale specialty pharmacy networks and comprehensive HAE patient registries

• High healthcare expenditure and robust rare disease insurance coverage

• Early adoption of oral, subcutaneous, and RNA-targeted HAE therapies

• Strong NIH/NIAID and FDA Orphan Drug Program funding for rare disease R&D

Restraints

• Very high cost of HAE biologics and specialty therapies per patient per year

• Stringent FDA regulatory requirements and long approval timelines

• Payer restrictions and prior authorization hurdles for novel agents

• Shortage of allergy/immunology specialists managing HAE patients

Opportunities

• Gene therapy and NTLA-2002 (Intellia) as potential single-treatment curative approaches

• Expansion of oral therapy used to pediatric populations

Canada Hereditary Angioedema Therapeutics Market Analysis:

Canada represented approximately 9.00% of the North American HAE therapeutics market in 2025 and was valued at around USD XX billion. The market is supported by increasing government healthcare spending on rare diseases, rising awareness of HAE among Canadian physicians, and a universal healthcare system that facilitates specialty drug access through public formularies and exceptional access programs.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Canada Hereditary Angioedema Therapeutics Market Size: USD 142 Million

• 2035 Canada Hereditary Angioedema Therapeutics Market Size: USD 339 Million

• Canada Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 9.60%

Drivers

• Universal healthcare coverage facilitating rare disease drug access

• Rising awareness of HAE and improvements in C1-INH testing

• Strong academic research institutions driving HAE clinical trials

• Expanding national rare disease strategy supporting orphan drug reimbursement

Restraints

• Smaller patient population vs. the U.S. limiting commercial viability

• Delays in provincial formulary listing of newly approved HAE therapies

• Limited manufacturing base for plasma-derived C1-INH products

• Geographic challenges in reaching patients in remote northern regions

Opportunities

• Precision medicine and pharmacogenomics approaches in HAE management

• U.S.-Canada cross-border collaboration for clinical trials and therapy access

Europe Hereditary Angioedema Therapeutics Market Analysis:

Europe accounted for approximately 31.20% of the global Hereditary Angioedema Therapeutics market in 2025 and was valued at nearly USD 988 Million. The European market benefits from strong EMA regulatory standards, well-established molecular diagnostic infrastructure.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Europe Hereditary Angioedema Therapeutics Market Size: USD 988 Million

• 2035 Europe Hereditary Angioedema Therapeutics Market Size: USD 2,162 Million

• Europe Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 8.56%

Drivers

• Strong EMA regulatory standards and Orphan Medicinal Product framework

• Well-established allergy/immunology networks and ACARE centers across Europe

• Growing adoption of prophylactic and on-demand HAE therapies across EU member states

• Significant EU research funding for rare disease genomics and novel therapeutics

Restraints

• Fragmented reimbursement landscape across EU member states

• Reimbursement timeline variability: 3 months in Germany to 3 years in some Eastern EU countries

• Budget constraints in Eastern and Southern European healthcare systems

• Competition from lower-cost biosimilar C1-INH products in price-sensitive markets

Opportunities

• EU regulatory harmonization accelerating market access across all 27 member states

• Expansion of oral HAE therapies reducing injection burden for European patients

United Kingdom Hereditary Angioedema Therapeutics Market Analysis:

The UK represented approximately 16.20% of the European HAE therapeutics market in 2025 and was valued at nearly USD 160 Million. The market is supported by the NHS Highly Specialized Services framework for rare diseases, a network of UK HAE centers, and strong clinical research activities through institutions such as UCL and Newcastle University.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 UK Hereditary Angioedema Therapeutics Market Size: USD 160 Million

• 2035 UK Hereditary Angioedema Therapeutics Market Size: USD 357 Million

• UK Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 8.50%

Drivers

• NHS Highly Specialized Services framework supporting rare disease therapy funding

• Active UK HAE network providing coordinated specialist care

• Genomic Medicine Service investments enabling earlier genetic diagnosis

• COVID-19 testing infrastructure established robust molecular diagnostic capacity

Restraints

• Post-Brexit regulatory divergence creating delays vs. EU marketing authorization timelines

• NHS budget constraints and NICE health technology assessment pricing pressures

• Reimbursement challenges for high-cost novel biological HAE therapies

• Molecular pathology and allergy/immunology workforce shortages

Opportunities

• NHS Genomic Medicine Service expansion enabling HAE family-based screening

• Growth of RNA-targeted prophylactic therapies in NHS specialized commissioning

Germany Hereditary Angioedema Therapeutics Market Analysis:

Germany accounted for approximately 22.20% of the European HAE therapeutics market in 2025 and was valued at around USD 219 Million. Germany is the leading European country for HAE diagnosis and treatment, operating the GSAR (German Society for Angioedema Research) network and multiple HAE reference centers.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Germany Hereditary Angioedema Therapeutics Market Size: USD 219 Million

• 2035 Germany Hereditary Angioedema Therapeutics Market Size: USD 486 Million

• Germany Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 8.60%

Drivers

• AMNOG framework enabling immediate market access for newly approved rare disease therapies

• GSAR network and multiple HAE reference centers supporting expert diagnosis

• Strong biotech and pharmaceutical industry presence (Bayer, Biotest)

• Robust healthcare system with comprehensive rare disease insurance coverage

Restraints

• High labor and operational costs for specialty pharmacy networks

• Stringent AMNOG price negotiation post-launch potentially reducing HAE therapy revenues

• Data protection regulations affecting patient registry data collection

• Aging population creating additional cost pressures on the public health system

Opportunities

• First European launch market for EKTERLY reinforcing Germany's role as HAE therapeutic leader

• Expanding RNA-targeted prophylaxis therapies via German allergy centers

France Hereditary Angioedema Therapeutics Market Analysis:

France represented approximately 13.10% of the European HAE therapeutics market in 2025 and was valued at nearly USD 129 Million. France has published national HAE guidelines through CREAK (French National Reference Center for Angioedema) and maintains one of Europe's highest numbers of diagnosed HAE patients.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 France Hereditary Angioedema Therapeutics Market Size: USD 129 Million

• 2035 France Hereditary Angioedema Therapeutics Market Size: USD 288 Million

• France Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 8.40%

Drivers

• CREAK national reference center for angioedema coordinating diagnosis and treatment

• National genomics plan (France Genomic Medicine 2025) driving rare disease testing

• Strong clinical research base including Institute Pasteur supporting HAE research

• Government support for rare disease (Plan Maladies Rares) therapeutics investment

Restraints

• Bureaucratic HAS reimbursement process with prolonged review timelines

• Competition from established European HAE therapy manufacturers

• Reimbursement variability across French insurance schemes

• Economic constraints on adoption of high-cost novel biologics

Opportunities

• National rare disease plan expanding access to novel HAE prophylactic therapies

• Expansion of oral on-demand therapy (sebetralstat) into French clinical practice

Italy Hereditary Angioedema Therapeutics Market Analysis:

Italy accounted for approximately 10.30% of the European HAE therapeutics market in 2025 and was valued at around USD 102 Million. Italy operates the ITACA (Italian network for hereditary and acquired angioedema) network, which coordinates HAE diagnosis and management across specialist centers.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Italy Hereditary Angioedema Therapeutics Market Size: USD 102 Million

• 2035 Italy Hereditary Angioedema Therapeutics Market Size: USD 212 Million

• Italy Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 7.90%

Drivers

• ITACA network supporting coordinated HAE diagnosis and specialist management

• Rising demand for both prophylactic and on-demand HAE therapies

• Government rare disease legislation (Law 648/96) supporting off-label HAE drug access

• Active participation in European HAE clinical trials and guidelines development

Restraints

• High cost of advanced HAE biologic and RNA-targeted therapies

• AIFA reimbursement delays for newly approved orphan medicines

• Shortage of allergy/immunology HAE specialists in Southern Italy

• Regulatory compliance requirements for orphan drug tracking systems

Opportunities

• Expansion of precision medicine programs including genetic testing for HAE families

• Growth of self-administered subcutaneous HAE prophylactic therapies

Spain Hereditary Angioedema Therapeutics Market Analysis:

Spain represented approximately 8.70% of the European HAE therapeutics market in 2025 and was valued at nearly USD 86 Million. Spain's SEAIC (Spanish Society of Allergology and Clinical Immunology) has published national HAE guidelines and participates actively in European HAE networks.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Spain Hereditary Angioedema Therapeutics Market Size: USD 86 Million

• 2035 Spain Hereditary Angioedema Therapeutics Market Size: USD 199 Million

• Spain Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 9.20%

Drivers

• SEAIC national HAE guidelines and specialist center network supporting diagnosis

• Rising incidence awareness and C1-INH testing capabilities across Spanish hospitals

• Government rare disease strategy supporting orphan medicine reimbursement

• Expanding use of molecular diagnostics in oncology and genetic disorder settings

Restraints

• High cost of advanced HAE kallikrein inhibitor and RNA-targeted therapies

• Budget constraints in the decentralized Spanish regional health system

• Shortage of specialized allergy/immunology HAE professionals in rural regions

• Variability in SNS reimbursement across Spanish autonomous communities

Opportunities

• Growth of oral kallikrein inhibitor prophylaxis expanding patient access

• Adoption of digital telemedicine platforms expanding HAE monitoring

Switzerland Hereditary Angioedema Therapeutics Market Analysis:

Switzerland accounted for approximately 6.70% of the European HAE therapeutics market in 2025 and was valued at around USD 66 Million. Switzerland approved EKTERLY (sebetralstat) alongside the EU in September 2025 through Swissmedic, with availability anticipated in the second half of 2026 pending reimbursement finalization.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Switzerland Hereditary Angioedema Therapeutics Market Size: USD 66 Million

• 2035 Switzerland Hereditary Angioedema Therapeutics Market Size: USD 156 Million

• Switzerland Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 9.40%

Drivers

• Swissmedic approval of sebetralstat (EKTERLY) in September 2025 alongside EMA

• Strong pharmaceutical ecosystem facilitating HAE therapy access

• High per-capita healthcare expenditure supporting specialty rare disease funding

• Growing rare disease registry and precision medicine investments

Restraints

• High cost of HAE therapies relative to Swissmedic reimbursement framework

• Stringent SwissDRG reimbursement negotiations for novel biologics

• Limited HAE specialist centers for a relatively small patient population

• Skilled workforce shortages in specialized allergy/immunology diagnostics

Opportunities

• Expansion of EKTERLY commercial availability from 2026 following reimbursement finalization

• Increasing investment in genomic research supporting HAE genetic counseling

Netherlands Hereditary Angioedema Therapeutics Market Analysis:

The Netherlands represented approximately 6.20% of the European HAE therapeutics market in 2025 and was valued at nearly USD 61 Million. The Netherlands hosts leading research institutions (Amsterdam UMC) and actively participates in European HAE clinical networks.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Netherlands Hereditary Angioedema Therapeutics Market Size: USD 61 Million

• 2035 Netherlands Hereditary Angioedema Therapeutics Market Size: USD 143 Million

• Netherlands Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 9.00%

Drivers

• Growing demand for prophylactic and on-demand HAE therapies

• Expansion of C1-INH genetic testing and diagnostic services

• Rising cancer and rare disease screening driving molecular testing demand

• Increasing adoption of subcutaneous self-administered HAE prophylaxis

Restraints

• High cost of advanced HAE biologics and RNA-targeted therapies

• NZa reimbursement delays for newly approved orphan medicines

• Need for specialized technical expertise limiting HAE therapy management

• Dependence on imported biopharmaceutical products for plasma-derived C1-INH

Opportunities

• Growth in genomics and molecular rare disease research supporting HAE diagnostics

• Increasing adoption of oral HAE therapies improving patient quality of life

Asia Pacific Hereditary Angioedema Therapeutics Market Analysis:

Asia Pacific accounted for approximately 11.60% of the global Hereditary Angioedema Therapeutics market in 2025 and represents the fastest-growing regional market. HAE is significantly underdiagnosed in the region due to limited C1-INH testing availability, low physician awareness, and insufficient access to guideline-recommended therapies.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Asia Pacific Hereditary Angioedema Therapeutics Market Size: USD 367 Million

• 2035 Asia Pacific Hereditary Angioedema Therapeutics Market Size: USD 1,210 Million

• Asia Pacific Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 8.56%

Drivers

• Rising rare disease awareness and healthcare investments in key Asia Pacific markets

• Expanding molecular diagnostic capabilities enabling earlier HAE diagnosis

• Growing patient advocacy and HAE support group activities across the region

• Increasing biologics access in Japan, South Korea, Australia, and Singapore

Restraints

• Significant underdiagnosis of HAE due to limited C1-INH testing access

• Lack of regional Asia Pacific-specific HAE guidelines

• Very high cost of biologic HAE therapies limiting access in developing markets

• Only minority of countries have HAE-specific medications registered

Opportunities

• Expansion of HAE diagnostic testing and specialist training programs

• Biosimilar C1-INH product development reducing treatment costs in the region

China Hereditary Angioedema Therapeutics Market Analysis:

China accounted for approximately 32.00% of the Asia Pacific HAE therapeutics market in 2025. China has a large patient population that remains largely undiagnosed due to low awareness and limited access to C1-INH diagnostic testing in many provinces.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 China Hereditary Angioedema Therapeutics Market Size: USD 117 Million

• 2035 China Hereditary Angioedema Therapeutics Market Size: USD 417 Million

• China Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 11.50%

Drivers

• Large patient population driving demand for HAE therapeutics

• Government rare disease list inclusion (2018) promoting HAE diagnosis and treatment

• Expanding NMPA regulatory capacity for rare disease biologic approvals

• Growing government R&D investments in biologics and rare disease genomics

Restraints

• Significant underdiagnosis of HAE due to limited specialist awareness

• Very high cost of imported biologic HAE therapies limiting patient access

• Lack of locally developed plasma fractionation and C1-INH manufacturing capacity

• Shortage of allergy/immunology specialists trained in HAE management

Opportunities

• Local biopharmaceutical company investments in rare disease therapy development

• Expansion of government-funded rare disease patient assistance programs

Japan Hereditary Angioedema Therapeutics Market Analysis:

Japan accounted for approximately 27.00% of the Asia Pacific HAE therapeutics market in 2025. Japan has published national HAE guidelines and has approved multiple HAE therapies including C1-INH concentrates, icatibant (Firazyr), and lanadelumab (Takhzyro).

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Japan Hereditary Angioedema Therapeutics Market Size: USD 99 Million

• 2035 Japan Hereditary Angioedema Therapeutics Market Size: USD 272 Million

• Japan Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 7.30%

Drivers

• Established national HAE guidelines and PMDA rare disease approval pathway

• Approval of key HAE therapies including icatibant and lanadelumab

• Active participation of Japanese Society of Allergology in HAE guideline development

• Pending sebetralstat (EKTERLY) regulatory review by PMDA supporting market growth

Restraints

• High cost of approved HAE biologic therapies under NHI pricing constraints

• Regulatory review timelines for novel HAE therapies via PMDA

• Limited HAE specialist centers outside major urban areas

• Low HAE awareness among general practitioners causing diagnostic delays

Opportunities

• Oral kallikrein inhibitor approvals expected to significantly expand patient access

• Growing investment in Japanese rare disease patient registries improving diagnosis rates

India Hereditary Angioedema Therapeutics Market Analysis:

India accounted for approximately 10.00% of the Asia Pacific HAE therapeutics market in 2025. HAE remains markedly underdiagnosed in India, with very limited access to C1-INH laboratory testing and few accredited allergy/immunology centers outside major metropolitan areas.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 India Hereditary Angioedema Therapeutics Market Size: USD 37 Million

• 2035 India Hereditary Angioedema Therapeutics Market Size: USD 163 Million

• India Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 14.20%

Drivers

• Growing healthcare infrastructure investments including specialty hospital expansion

• CDSCO approval of icatibant providing an on-demand HAE therapy option

• Rising rare disease awareness among Indian allergy/immunology specialists

• Increasing private sector investment in biopharmaceutical manufacturing

Restraints

• Severe underdiagnosis due to limited C1-INH laboratory testing access

• Very high cost of imported biologic HAE therapies relative to per-capita income

• Lack of a comprehensive national rare disease policy with targeted HAE funding

• Shortage of allergy/immunology HAE specialists outside metropolitan cities

Opportunities

• Development of affordable generic or biosimilar HAE therapy options

• National rare disease policy improvements expanding HAE therapy reimbursement

South Korea Hereditary Angioedema Therapeutics Market Analysis:

South Korea represented approximately 8.40% of the Asia Pacific HAE therapeutics market in 2025. South Korea has a well-developed healthcare system and a national rare disease support program through the Korea Disease Control and Prevention Agency (KDCA).

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 South Korea Hereditary Angioedema Therapeutics Market Size: USD 31 Million

• 2035 South Korea Hereditary Angioedema Therapeutics Market Size: USD 115 Million

• South Korea Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 10.5%

Driver

• National rare disease support program through KDCA facilitating HAE access

• MFDS approval of key HAE therapies including lanadelumab and C1-INH concentrates

• Advanced healthcare infrastructure and digital health capabilities

• Active South Korean clinical research participation in HAE studies

Restraints

• High cost of approved HAE biologics relative to national health insurance coverage

• Limited HAE specialist centers outside Seoul and major cities

• Regulatory delays for novel HAE therapies pending MFDS review

• Low public awareness of hereditary angioedema symptoms and diagnosis

Opportunities

• Expansion of oral kallikrein inhibitor therapies increasing patient adherence

• Digital health and telemedicine platforms improving HAE monitoring and management

Australia Hereditary Angioedema Therapeutics Market Analysis:

Australia accounted for approximately 9.60% of the Asia Pacific HAE therapeutics market in 2025. Australia has published national HAE consensus guidelines coordinated by ASCIA (Australasian Society of Clinical Immunology and Allergy) and has approved multiple HAE therapies through the Therapeutic Goods Administration (TGA).

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Australia Hereditary Angioedema Therapeutics Market Size: USD 35 million

• 2035 Australia Hereditary Angioedema Therapeutics Market Size: USD 103 Million

• Australia Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 7.80%

Drivers

• National ASCIA HAE guidelines and PBS subsidized HAE therapy access

• TGA approval of key HAE treatments including icatibant and C1-INH concentrates

• Active clinical research community driving HAE awareness and new therapy adoption

• Growing patient advocacy through Australasian HAE patient organizations

Restraints

• High cost of novel biologic HAE therapies prior to PBS listing

• Geographic challenges in reaching rural and remote HAE patients

• Limited number of HAE specialist centers outside major metropolitan areas

• TGA regulatory review timelines for new HAE biologics and RNA-targeted agents

Opportunities

• PBS listing of newer HAE prophylactic therapies expected to drive patient volume growth

• Telehealth platforms enabling remote HAE specialist consultations across Australia

Singapore Hereditary Angioedema Therapeutics Market Analysis:

Singapore represented approximately 2.70% of the Asia Pacific HAE therapeutics market in 2025. Singapore's Health Sciences Authority (HSA) has approved select HAE therapies. Singapore serves as a regional hub for clinical trials and biopharmaceutical distribution across Southeast Asia.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Singapore Hereditary Angioedema Therapeutics Market Size: USD 10 Million

• 2035 Singapore Hereditary Angioedema Therapeutics Market Size: USD 30 Million

• Singapore Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 7.20%

Drivers

• Rare Disease Fund providing patient access support for HAE therapies

• Singapore as regional hub for biopharmaceutical clinical trials and drug distribution

• Advanced healthcare infrastructure supporting specialist allergy/immunology care

• Active HSA regulatory framework facilitating rare disease therapy approvals

Restraints

• Small patient population limiting commercial attractiveness for HAE market entry

• High cost of imported HAE biologic therapies relative to public healthcare budget

• Limited local pharmaceutical manufacturing capacity for HAE products

• Dependence on imported therapies from the U.S., Europe, and Japan

Opportunities

• Regional HAE clinical trial hub function expanding Singapore's market position

• Digital health platforms improving HAE patient monitoring and specialist access

Thailand Hereditary Angioedema Therapeutics Market Analysis:

Thailand accounted for approximately 310% of the Asia Pacific HAE therapeutics market in 2025. HAE is significantly underdiagnosed in Thailand due to limited C1-INH testing and low physician awareness. The Food and Drug Administration (Thai FDA) has approved limited HAE therapy options.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Thailand Hereditary Angioedema Therapeutics Market Size: USD 11 Million

• 2035 Thailand Hereditary Angioedema Therapeutics Market Size: USD 51 Million

• Thailand Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 13.50%

Drivers

• Growing private hospital network expanding specialty care access

• Increasing rare disease awareness among Thai allergy/immunology specialists

• Government Universal Health Coverage scheme providing rare disease support

• Rising healthcare expenditure supporting specialty pharmaceutical adoption

Restraints

• Limited C1-INH diagnostic testing access outside Bangkok and major cities

• Very high cost of imported biologic HAE therapies relative to Thai healthcare budgets

• Low physician awareness of HAE causing extended diagnostic delays

• Limited HAE-specific patient support programs or advocacy groups

Opportunities

• Expansion of private sector rare disease services improving HAE diagnosis rates

• Regional collaboration with Asian HAE centers providing clinical expertise transfer

Malaysia Hereditary Angioedema Therapeutics Market Analysis:

Malaysia represented approximately 2.50% of the Asia Pacific HAE therapeutics market in 2025. HAE remains largely underdiagnosed in Malaysia. The National Pharmaceutical Regulatory Agency (NPRA) oversees drug approval. Malaysia has limited HAE specialty centers, primarily in Kuala Lumpur.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Malaysia Hereditary Angioedema Therapeutics Market Size: USD 9 Million

• 2035 Malaysia Hereditary Angioedema Therapeutics Market Size: USD 38 Million

• Malaysia Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 11.80%

Drivers

• Expanding Ministry of Health rare disease framework covering HAE

• Growing private hospital sector facilitating specialty rare disease care

• Rising healthcare expenditure supporting specialty biologics access

• Increasing medical education on rare disease diagnosis among Malaysian doctors

Restraints

• Significant underdiagnosis of HAE due to limited specialist awareness

• High cost of imported HAE biologic therapies relative to local healthcare budgets

• Limited NPRA regulatory infrastructure for rare disease orphan drug approvals

• Shortage of trained allergy/immunology specialists for HAE management

Opportunities

• HAE specialist training programs through regional APAAACI collaboration

• Growing investment in molecular diagnostics improving C1-INH testing access

Indonesia Hereditary Angioedema Therapeutics Market Analysis:

Indonesia accounted for approximately 3.40% of the Asia Pacific HAE therapeutics market in 2025. With a population exceeding 275 million, Indonesia has a very large potential HAE patient pool that remains almost entirely undiagnosed. The National Agency of Drug and Food Control (BPOM) oversee drug approvals.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Indonesia Hereditary Angioedema Therapeutics Market Size: USD 12 Million

• 2035 Indonesia Hereditary Angioedema Therapeutics Market Size: USD 53 Million

• Indonesia Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 13.20%

Drivers

• Very large potential patient population across the archipelago

• Growing JKN national health insurance expansion including rare disease coverage

• Rising private sector investments in Indonesian hospital infrastructure

• Increasing BPOM engagement with international rare disease regulatory frameworks

Restraints

• Extremely limited HAE diagnostic testing outside Jakarta

• High cost of imported biologic HAE therapies relative to local purchasing power

• Very low physician awareness of HAE across Indonesia's diverse healthcare workforce

• Geographic challenges in reaching patients across 17,000 islands

Opportunities

• Long-term growth potential as HAE awareness and JKN rare disease coverage expand

• Potential for regional telemedicine programs improving HAE specialist access

Middle East & Africa Hereditary Angioedema Therapeutics Market Analysis:

The Middle East & Africa (MEA) accounted for approximately 2.90% of the global Hereditary Angioedema Therapeutics market in 2025. HAE is significantly underdiagnosed across much of the MEA region due to limited specialist care access, restricted availability of C1-INH testing, and low public health awareness.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Middle East & Africa Hereditary Angioedema Therapeutics Market Size: USD 92 Million

• 2035 Middle East & Africa Hereditary Angioedema Therapeutics Market Size: USD 216 Million

• Middle East & Africa Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 8.56%

Drivers

• Growing national rare disease programs in Saudi Arabia and UAE

• Rising healthcare expenditure in GCC countries driving specialty pharma adoption

• Expanding hospital networks and specialist allergy/immunology centers in MEA

• Increasing awareness of rare hereditary disorders among MEA physicians

Restraints

• Significant HAE underdiagnosis due to limited C1-INH testing infrastructure

• High cost of biologic HAE therapies exceeding healthcare budgets in many MEA countries

• Variability in regulatory frameworks for orphan drug approval across MEA countries

• Shortage of allergy/immunology specialists with HAE expertise across the region

Opportunities

• Saudi Vision 2030 healthcare transformation driving rare disease awareness and treatment

• Expansion of UAE and Saudi HAE reference centers attracting regional patients

Saudi Arabia Hereditary Angioedema Therapeutics Market Analysis:

Saudi Arabia represented approximately 20.00% of the MEA HAE therapeutics market in 2025.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Saudi Arabia Hereditary Angioedema Therapeutics Market Size: USD 18 Million

• 2035 Saudi Arabia Hereditary Angioedema Therapeutics Market Size: USD 50 Million

• Saudi Arabia Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 11.20%

Drivers

• Saudi Vision 2030 healthcare transformation driving specialist care investment

• SFDA approvals of key HAE biologic therapies including C1-INH and kallikrein inhibitors

• High government healthcare spending supporting rare disease therapy access

• Growing number of allergology and immunology specialist centers across Saudi cities

Restraints

• Limited public awareness of HAE as a rare genetic disease

• Dependence on imported biologic therapies with high associated costs

• Lack of local plasma fractionation infrastructure for C1-INH production

• Shortage of allergy/immunology specialists trained in HAE management outside Riyadh/Jeddah

Opportunities

• Vision 2030 rare disease initiative expected to expand HAE diagnosis and treatment access

• Growing medical tourism attracts HAE patients from across the Middle East

United Arab Emirates Hereditary Angioedema Therapeutics Market Analysis:

The UAE accounted for approximately 13.00% of the MEA HAE therapeutics market in 2025. The UAE's Ministry of Health and Prevention (MoHAP) oversees drug approvals. The UAE operates a well-resourced healthcare system in Dubai and Abu Dhabi, with multiple specialist allergy/immunology centers.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 United Arab Emirates Hereditary Angioedema Therapeutics Market Size: USD 12 Million

• 2035 United Arab Emirates Hereditary Angioedema Therapeutics Market Size: USD 35 Million

• United Arab Emirates Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 11.50%

Drivers

• MoHAP approval of key HAE acute therapies in UAE healthcare facilities

• Well-resourced healthcare systems in Dubai and Abu Dhabi support specialty care

• UAE National Rare Diseases Office coordinating rare disease diagnostic programs

• High per-capita healthcare expenditure supporting expensive biologic therapy access

Restraints

• Small national patient population with HAE diagnosis limiting commercial viability

• Dependence on imported HAE biologic therapies increasing treatment costs

• Limited HAE specialist centers outside major urban areas

• Low public awareness of hereditary angioedema as a rare genetic disease

Opportunities

• UAE Healthcare Vision expanding specialty biopharmaceutical therapy access

• Medical tourism hub role attracting HAE patients from the broader GCC region

South Africa Hereditary Angioedema Therapeutics Market Analysis:

South Africa represented approximately 33.00% of the MEA HAE therapeutics market in 2025. South Africa has the most developed pharmaceutical regulatory framework on the African continent, managed by the South African Health Products Regulatory Authority (SAHPRA).

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 South Africa Hereditary Angioedema Therapeutics Market Size: USD 30 Million

• 2035 South Africa Hereditary Angioedema Therapeutics Market Size: USD 60 Million

• South Africa Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 7.30%

Drivers

• SAHPRA rare disease approval pathway supporting HAE therapy registration

• Academic medical centers with rare disease immunology expertise

• Growing private health insurance sector enabling specialty pharma access

• Rising physician awareness of HAE through international medical education programs

Restraints

• High cost of imported biologic HAE therapies relative to public healthcare budgets

• Very limited HAE diagnostic testing outside major South African cities

• Severe healthcare inequity between private and public hospital systems

• Shortage of allergy/immunology specialists with HAE expertise

Opportunities

• Expansion of South African rare disease registry supporting HAE epidemiological data

• Regional leadership role for sub-Saharan Africa HAE awareness initiatives

Egypt Hereditary Angioedema Therapeutics Market Analysis:

Egypt accounted for approximately 6.50% of the MEA HAE therapeutics market in 2025. Egypt has limited approved HAE therapy options through the Egyptian Drug Authority (EDA). HAE awareness among Egyptian allergists is growing, supported by collaboration with HAE International and regional allergy societies.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Egypt Hereditary Angioedema Therapeutics Market Size: USD 6 Million

• 2035 Egypt Hereditary Angioedema Therapeutics Market Size: USD 17 Million

• Egypt Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 10.50%

Drivers

• Growing HAE awareness among Egyptian allergology and immunology specialists

• Large patient population providing significant potential for HAE diagnosis expansion

• Increasing EDA engagement with international rare disease regulatory frameworks

• Rising healthcare expenditure and hospital infrastructure investment

Restraints

• Limited EDA-approved HAE therapy options and restricted formulary coverage

• High cost of imported biologic HAE therapies relative to Egyptian healthcare budgets

• Very limited C1-INH laboratory testing infrastructure outside Cairo

• Shortage of allergy/immunology specialists with HAE clinical training

Opportunities

• Regional HAE awareness programs through Egyptian Society of Allergy and Clinical Immunology

• Potential international pharmaceutical company patient assistance program expansion

Israel Hereditary Angioedema Therapeutics Market Analysis:

Israel represented approximately 17.50% of the MEA HAE therapeutics market in 2025. Israel has a well-developed healthcare system with multiple approved HAE therapies including C1-INH concentrates, icatibant, and lanadelumab, supported by the Ministry of Health and the National Institute for Health Policy Research.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Israel Hereditary Angioedema Therapeutics Market Size: USD 16 Million

• 2035 Israel Hereditary Angioedema Therapeutics Market Size: USD 40 Million

• Israel Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 9.20%

Drivers

• National Health Insurance Law ensuring coverage for approved rare disease therapies

• Multiple approved HAE therapies including lanadelumab and C1-INH concentrates

• Active Israeli HAE clinical research community participating in global trials

• Well-developed allergy/immunology specialist network managing HAE patients

Restraints

• Budgetary constraints within the National Health Insurance basket for high-cost therapies

• Regulatory delays for very recently approved therapies including sebetralstat

• Small patient population limiting market commercial scale

• Limited local manufacturing capacity for biologic HAE therapies

Opportunities

• Expansion of Israeli HAE clinical trials supporting early access to pipeline therapies

• Growing investment in genomic medicine facilitating HAE family-based genetic screening

Latin America Hereditary Angioedema Therapeutics Market Analysis:

Latin America accounted for approximately 4.50% of the global Hereditary Angioedema Therapeutics market in 2025. Brazil, Mexico, and Argentina represent the largest markets in the region. HAE remains significantly underdiagnosed across Latin America, though awareness is growing. Several countries in the region have published national HAE guidelines.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Latin America Hereditary Angioedema Therapeutics Market Size: USD 142 Million

• 2035 Latin America Hereditary Angioedema Therapeutics Market Size: USD 389 Million

• Latin America Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 8.56%

Drivers

• Growing HAE awareness and physician education programs across Latin America

• National HAE guidelines published in Brazil, Argentina, and other key markets

• Rising healthcare expenditure in key Latin American economies

• Increasing adoption of rare disease patient assistance programs by global pharma companies

Restraints

• Significant HAE underdiagnosis across Latin America outside major cities

• High cost of biologic HAE therapies relative to Latin American healthcare budgets

• Regulatory variability and lengthy approval timelines across LATAM national agencies

• Limited C1-INH diagnostic testing access in rural and remote regions

Opportunities

• Expanding rare disease policy frameworks supporting HAE therapy reimbursement

• Growing biopharmaceutical investments in Brazil and Mexico facilitating market access

Brazil Hereditary Angioedema Therapeutics Market Analysis:

Brazil represented approximately 44.00% of the Latin America HAE therapeutics market in 2025. Brazil has the most advanced HAE therapeutics market in Latin America, with published national guidelines by the Brazilian Association of Allergy and Immunology (ASBAI) and an active patient organization (ABRA).

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Brazil Hereditary Angioedema Therapeutics Market Size: USD 62 Million

• 2035 Brazil Hereditary Angioedema Therapeutics Market Size: USD 163 Million

• Brazil Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 8.30%

Drivers

• ASBAI national HAE guidelines and active ABRA patient organization driving awareness

• SUS access to select approved HAE therapies including C1-INH concentrates

• ANVISA approval framework for rare disease orphan medicines

• Growing investment in Brazilian biopharmaceutical manufacturing and clinical trials

Restraints

• Limited SUS budget for high-cost biologic HAE therapies

• Regulatory delays in ANVISA approval of novel HAE pipeline agents

• Geographic access challenges in reaching HAE patients in interior Brazil

• Shortage of allergy/immunology specialists outside São Paulo and Rio de Janeiro

Opportunities

• Expansion of private healthcare access broadening HAE biologic therapy availability

• Growing Brazilian HAE clinical trial participation supporting early therapy access

Mexico Hereditary Angioedema Therapeutics Market Analysis:

Mexico accounted for approximately 23.00% of the Latin America HAE therapeutics market in 2025. Mexico's Federal Commission for Protection against Sanitary Risk (COFEPRIS) has approved key HAE therapies including C1-INH products.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Mexico Hereditary Angioedema Therapeutics Market Size: USD 33 Million

• 2035 Mexico Hereditary Angioedema Therapeutics Market Size: USD 97 Million

• Mexico Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 9.60%

Drivers

• COFEPRIS approval of key HAE therapies including C1-INH concentrates

• Growing HAE awareness through Mexican College of Immunology and Allergy activities

• IMSS and ISSSTE social security coverage for select rare disease therapies

• Increasing private healthcare sector expansion supporting specialty biologic access

Restraints

• High cost of imported biologic HAE therapies relative to public healthcare budgets

• Limited access to HAE specialist centers outside Mexico City

• Regulatory delays for new HAE therapy approvals through COFEPRIS

• Shortage of trained allergy/immunology specialists for HAE management in rural areas

Opportunities

• Expansion of private health insurance covering innovative HAE biologics

• Growing participation in international HAE patient registries improving epidemiological data

Argentina Hereditary Angioedema Therapeutics Market Analysis:

Argentina represented approximately 10.20% of the Latin America HAE therapeutics market in 2025. Argentina has published national HAE guidelines through the Argentine Society of Allergology and Clinical Immunology (SAAIC) and has one of the more active HAE clinical communities in Latin America.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Argentina Hereditary Angioedema Therapeutics Market Size: USD 14 Million
• 2035 Argentina Hereditary Angioedema Therapeutics Market Size: USD 37 Million
• Argentina Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 7.60%

Drivers

• SAAIC national HAE guidelines and active Argentine clinical research community
• ANMAT approval framework supporting HAE therapy market access
• Ministry of Health funding for selecting rare disease therapies
• Growing HAE patient advocacy group activities in Argentina

Restraints

• Economic instability limiting public healthcare budget for high-cost HAE therapies
• Dependence on imported biologic HAE products with associated currency risk
• Limited access to HAE specialist care outside Buenos Aires
• ANMAT regulatory delays for newly approved global HAE therapies

Opportunities

• Expansion of HAE patient assistance programs by global biopharmaceutical companies
• Growing Argentine biopharmaceutical sector supporting local HAE therapy production

Chile Hereditary Angioedema Therapeutics Market Analysis:

Chile accounted for approximately 5.80% of the Latin America HAE therapeutics market in 2025. Chile's Instituto de Salud Publica (ISP) oversees drug approvals. Chile has a relatively advanced healthcare system with growing rare disease awareness

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Chile Hereditary Angioedema Therapeutics Market Size: USD 8 Million
• 2035 Chile Hereditary Angioedema Therapeutics Market Size: USD 25 Million
• Chile Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 9.50%

Drivers

• Relatively advanced healthcare infrastructure supporting rare disease specialty care
• ISP approval of key HAE therapies including icatibant
• SEAICH educational activities driving HAE awareness among Chilean physicians
• FONASA and ISAPRE healthcare coverage providing partial access to specialty therapies

Restraints

• High cost of imported biologic HAE therapies relative to Chilean healthcare budgets
• Limited HAE specialist centers outside Santiago
• Geographic challenges in reaching HAE patients in remote Chilean regions
• Limited HAE epidemiological data in Chile

Opportunities

• Expansion of HAE genetic screening and diagnostic testing in Chilean public hospitals
• Growing private sector healthcare investment broadening specialty pharmaceutical access

Colombia Hereditary Angioedema Therapeutics Market Analysis:

Colombia represented approximately 8.20% of the Latin America HAE therapeutics market in 2025. Colombia's INVIMA (National Institute of Drug and Food Surveillance) oversees drug approvals. Growing healthcare accessibility and rising rare disease awareness are driving gradual market expansion.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Colombia Hereditary Angioedema Therapeutics Market Size: USD 12 Million
• 2035 Colombia Hereditary Angioedema Therapeutics Market Size: USD 35 Million
• Colombia Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 9.30%

Drivers

• Rising prevalence awareness of rare diseases including hereditary angioedema
• INVIMA rare disease drug approval pathway supporting HAE market access
• EPS statutory healthcare coverage providing a reimbursement framework
• Expanding diagnostic laboratory services and allergy clinic infrastructure

Restraints

• Limited access to advanced HAE diagnostics in rural regions
• High costs associated with biologic HAE therapy related to local healthcare budgets
• Dependence on imported biologic and specialty HAE treatments
• Shortage of trained allergy/immunology specialists managing HAE

Opportunities

• Expansion of healthcare infrastructure projects improving rare disease access
• Growth of decentralized and point-of-care testing for C1-INH deficiency

Peru Hereditary Angioedema Therapeutics Market Analysis:

Peru represented approximately 3.70% of the Latin America HAE therapeutics market in 2025 and was valued at around USD 5 million. The market is characterized by increasing rare disease awareness, limited but growing HAE diagnostic capabilities, and gradual expansion of specialty pharmaceutical access through Lima-based specialist centers.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Peru Hereditary Angioedema Therapeutics Market Size: USD 5 Million
• 2035 Peru Hereditary Angioedema Therapeutics Market Size: USD 16 Million
• Peru Hereditary Angioedema Therapeutics Market CAGR (2026-2035): 8.40%

Drivers

• Rising awareness of rare genetic diseases including HAE among Peruvian physicians

• Expanding laboratory and diagnostic services in Lima and other major cities

• Growing healthcare expenditure supporting rare disease specialty pharmaceutical access

• Increasing participation in Latin American HAE epidemiological research

Restraints

• High cost of advanced HAE biologic platforms and imported therapies

• Limited HAE diagnostic and specialist care access in remote and rural areas

• Dependence on imported C1-INH and biologic HAE treatments

• Insufficient number of specialized allergy/immunology professionals

Opportunities

• Expansion of molecular diagnostic capabilities supporting earlier HAE detection

• Growth of point-of-care HAE testing solutions improving rural patient access

Hereditary Angioedema Therapeutics Market Key Players:

• Takeda Pharmaceutical Company Limited
• CSL Behring
• BioCryst Pharmaceuticals, Inc.
• KalVista Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Pharming Group N.V.
• Sanofi S.A.
• Arrowhead Pharmaceuticals, Inc.
• Intellia Therapeutics
• Pharvaris B.V.
• Regeneron Pharmaceuticals
• Novartis
• AstraZeneca
• Amgen
• Grifols
• Octapharma
• Pfizer
• GSK
• Bayer
• Merck
• AbbVie
• Eli Lilly and Company
• Bristol Myers Squibb
• Boehringer Ingelheim
• Sobi
• Chiesi Farmaceutici
• Fresenius Kabi
• Astria Therapeutics
• ADARx Pharmaceuticals
• Alnylam Pharmaceuticals
• Silence Therapeutics
• Verseau Therapeutics
• Spark Therapeutics
• Orchard Therapeutics
• Editas Medicine
• CRISPR Therapeutics
• Beam Therapeutics
• Sangamo Therapeutics
• Poseida Therapeutics
• uniQure

Hereditary Angioedema Therapeutics Market Recent Developments

• FDA Approval of EKTERLY (sebetralstat) – First Oral On-Demand HAE Therapy: In July 2025, the U.S. FDA approved EKTERLY (sebetralstat, KalVista Pharmaceuticals), the first and only oral plasma kallikrein inhibitor for acute HAE attacks in patients aged 12 and older. The KONFIDENT Phase 3 trial demonstrated symptom relief within 1.61 hours vs. 6.72 hours for placebo. EKTERLY was subsequently approved by the European Commission in September 2025, with Germany selected as the first European launch market.
• FDA Approval of DAWNZERA (donidalorsen) – First RNA-targeted HAE Prophylaxis: In August 2025, the FDA approved DAWNZERA (donidalorsen, Ionis Pharmaceuticals/Otsuka), the first and only RNA-targeted medicine for HAE prophylaxis in patients aged 12 and older. In the Phase 3 OASIS-HAE trial, DAWNZERA reduced mean monthly attack rates by 81% over 24 weeks with once-every-4-weeks dosing. The European Commission approved DAWNZERA in January 2026.
• FDA Approval of ANDEMBRY (garadacimab-gxii) – First Monthly Factor XIIa Inhibitor: In June 2025, CSL Behring received FDA approval for ANDEMBRY (garadacimab-gxii), the first once-monthly subcutaneous treatment targeting Factor XIIa to prevent HAE attacks in patients aged 12 and older.
• Gene Editing Therapy for HAE in Clinical Development: NTLA-2002 (Intellia Therapeutics) is an investigational in vivo gene-editing therapy designed as a systemically delivered, potentially one-time treatment to permanently reduce prekallikrein (PKK) protein levels by editing the responsible gene. Phase 2 clinical results demonstrated sustained HAE attack reduction, positioning NTLA-2002 as a potential functional cure.

Hereditary Angioedema Therapeutics Market Regulatory Landscape Analysis:

• United States (FDA) – Orphan Drug Designation, Breakthrough Therapy, Priority Review pathways
• European Union (EMA) – Orphan Medicinal Product designation, CHMP evaluation
• United Kingdom (MHRA) – Post-Brexit independent regulatory approvals
• Japan (PMDA) – Sakigake designation for innovative rare disease therapies
• India (CDSCO) – Orphan Drug rules under the New Drugs and Clinical Trials Rules 2019

Hereditary Angioedema Therapeutics Market Patent & IP Landscape

• Strict regulatory oversight for HAE biologics, small molecules, and gene therapies
• U.S. FDA regulates HAE therapeutics through Orphan Drug Act and biologics approval pathways
• EMA IVDR and biologics regulation govern HAE products across the EU
• Increasing emphasis on clinical validation, long-term safety data, and pediatric studies

Hereditary Angioedema Therapeutics Market Segmentations:

Our research framework strategically segments the Hereditary Angioedema Therapeutics market by drug class, treatment type, route of administration, end-user categories, and key regional markets

By Drug Class

• C1-Esterase Inhibitors (C1-INH)
• Kallikrein Inhibitors
• Bradykinin B2 Receptor Antagonists
• RNA-targeted Agents/Antisense Oligonucleotides
• Gene Therapy Candidates
• Others

By Treatment Type

• Prophylaxis (Long-term Prevention)
• On demand (Acute Attack Treatment)
• Short-term Prophylaxis (Pre-procedure)

By Route of Administration

• Subcutaneous
• Intravenous
• Oral

By End Use

• Hospitals & Specialty Clinics
• Specialty Pharmacies
• Home Care Settings
• Academic & Research Institutes
• Contract Research Organizations (CROs)

By Region & Country

North America

• United States
• Canada
• Mexico

Europe

• UK
• Germany
• France
• Italy
• Spain
• Switzerland
• Netherlands
• Denmark
• Sweden
• Norway
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• South Korea
• Australia
• Singapore
• Thailand
• Malaysia
• Indonesia
• Philippines
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Chile
• Colombia
• Peru
• Rest of Latin America

Middle East & Africa

• Saudi Arabia
• United Arab Emirates
• South Africa
• Egypt
• Israel
• Rest of Middle East & Africa

Key Report Attributes	Details
Years Considered	2022 to 2035
Market Size 2025	USD 3,165 Million
Market Size 2035	USD 7,205 Million
Historical CAGR % (Growth rate)	7.91% from 2022 to 2025
Futuristic CAGR % (Growth rate)	8.56% from 2026 to 2035
Segments Covered	By Type By Disease By Application By End-Use
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Switzerland, Netherlands, Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Singapore; Australia; Australia; Philippines; Indonesia; Brazil; Argentina; Indonesia; Chile; Colombia; Peru; South Africa; Egypt; Israel; Saudi Arabia; UAE; Kuwait
Competitive Landscape Overview	Merck KGaA Codexis, Inc. F. Hoffmann-La Roche Ltd. Amano Enzyme Inc. Advanced Enzymes Technologies Ltd. Biocatalysts Ltd. Amicogen Dyadic International BBI Solutions Affymetrix American Laboratories
Flexible Report Customization	The study can be customized based on geography, segment analysis, company profiling, competitive benchmarking, and strategic insights.
Data Sources	Primary and secondary sources used (Company filings, trade associations, Journals, Annual report, Publications, Surveys, Investor Presentations, and much more.